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Sources of data on HCV in Bangladesh in key populations at risk
of HIV are available through various sources. The last national HIV
surveillance conducted in Bangladesh in 2011 showed that in six
cities >50% of PWID had antibodies to HCV; in the capital city of
Dhaka, HCV prevalence among PWID was 39.6%. Information from
965 clients attending theHIV testing and counselling unit of icddr,b
in 2011where HCV antibodieswere also tested also conﬁrmed that
the highest rate was in PWID (37.1%) followed by clients of FSW
(1.6%) and less than 1% in others. Geographically, populations in
Dhaka, especially old Dhaka, appear to be especially vulnerable to
blood-borne infections such as HCV and HIV. In a study conducted
in 2015 among 84 HIV positive PWID in old Dhaka, 61% were also
positive for anti-HCV antibody. However, harm reduction services
have been active in Bangladesh and the needle syringe program is
among the best in South Asia. The prevalence of HCV has signiﬁ-
cantly declined in PWID in Dhaka since 1998 which appears to be
a direct result of these services.
Hepatitis C virus shows considerable sequence variability in its
genome and has at least 6 genotypes which respond differently
to available therapeutics. In Bangladesh, RNA from 81 samples
obtained through different studies at different times were ampli-
ﬁed for genotyping; 3a was the most prevalent (59.3%) followed by
3b (32.1%), 1b (4.9%), 1a (2.5%) and 3g (1.2%).
Newer, short-course, andwell-tolerated therapies have become
available and it is being suggested that “Treatment as Prevention”
be undertaken as a strategy in PWID to reduce onward HCV trans-
mission. Sucha strategy couldbecomepart of a comprehensiveHCV
disease elimination strategy.
http://dx.doi.org/10.1016/j.ijid.2016.02.134
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Abstract: Signiﬁcant progress has been made in treatment of
hepatitis C (HCV) infection since the virus was discovered over 26
years ago. After introduction of directly acting agents (DAAs), the
treatment for hepatitis C has signiﬁcantly improved both in efﬁcacy
and tolerability. Clinical trials using combinations of DAAs have
shown excellent sustained viral response rates (SVRs) in patients
with all HCV genotypes. Hepatitis C has now become a curable
disease from a chronic disease, and complications such as liver cir-
rhosis and hepatocellular carcinoma (HCC) are preventable. Given
the safety and efﬁcacy, treatment of HCV can move to the realm
of primary care physicians. However, with availability of multi-
ple DAAs in the market and several more on the pipeline, it has
becomemore complex todecidewhich combination therapywould
be more appropriate for individual patients. Additionally, despite
an abundance of choices, the cost of drugs has become a major hin-
drance to access for many patients. This presentation will provide
an overview and update on treatment of hepatitis C infection.
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Abstract: Infection with HIV and HCV contributes substantially
to the global burden of disease, with an estimated 4-5 million
people living with both infections. The natural history of HIV and
HCV is signiﬁcantly impacted by the coexistence of the other virus.
Increases in all-cause, AIDS-related, and liver-related morbidity,
hospitalization, and mortality are noted, with accelerated liver dis-
ease progression and high rates of end-stage liver disease, even in
those receiving combination antiretroviral therapy (cART) Given
greater access to cART, the number of global deaths related to HIV
is falling. In contrast, the number of HCV- related liver deaths is
rising. Fortunately advances in the development of directly acting
antiviral (DAA) agents for the treatment of HCV now mean that
highly effective, all oral regimens with low toxicity can be use to
achieve sustained virological response (SVR) in themajority ofHIV-
HCV co-infected individuals. However high cost and limited access
to these drugs currently prevent theirwidespread use, especially in
low and middle income countries. This paper will review the epi-
demiological data on prevalence of HIV-HCV globally and discuss
the natural history of co-infection.Most recent data on trials of DAA
combination therapy in HIV positive people will be presented and
issues relevant to this population including drug-drug interactions
reviewed. Finally barriers to care and treatment relevant to global
settings will be discussed.
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Abstract:Outbreaksandsporadic casesofhepatitis Eoccurglob-
ally with large epidemics occurring in resource-limited regions
where there is over-crowding, unsanitary conditions and poor
health services including refugee camps and internally displaced
populations. The World Health Organization (WHO) estimates that
the virus infects 20 million people each year of which 3 million
are acute hepatitis cases and 56,600 die. Fulminant hepatic failure
is reported in those infected in the third trimester of pregnancy
in some regions. Hepatitis E virus (HEV) infection can lead to
hepatitis decompensation in those with pre-existing liver disease.
Chronic HEV infection has been reported in solid organ transplant
